Inclusion Criteria:

          1. Patient has histologically or cytologically confirmed metastatic uveal melanoma with
             predominant liver involvement

          2. Age 18 years or older and willing and able to provide informed consent

          3. WOCBP must have a negative serum pregnancy test documented with 72 hours of first
             administration of drug

          4. Sexually active and WOCBP, patient and partner must agree to use adequate
             contraception

          5. Normal organ and marrow function

          6. ECOG 0-1

          7. Life expectancy of 3 months or greater

        Exclusion Criteria:

          1. History of previous grade 3, life threatening immune related adverse event (irAE) from
             prior checkpoint inhibitor therapy

          2. Prior treatment with anti cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) therapy
             within 90 days of C1D1 of study treatment

          3. Prior anti-cancer therapy (systemic, regional or radiation) within 2 weeks of C1D1 of
             study treatment

          4. AEs from prior anticancer therapies that have not resolved to grade 1 or less, other
             than endocrine related irAEs for which patients are on appropriate replacement therapy
             (ie hypothyroidism, adrenal insufficiency, type 1 diabetes)

          5. History of or active autoimmune disease requiring systemic corticosteroid or
             immunosuppressive therapy. (Patients who have limited autoimmune disease not requiring
             systemic therapy or autoimmune disease that is unlikely to recur, such as ulcerative
             colitis s/p colectomy, will be allowed to enroll.)

          6. Serious medical risk factors involving any of the major organ systems such that the
             Investigator considers it unsafe for the patient to receive an experimental research
             drug.

          7. Patient is unwilling or unable to comply with study procedures

          8. Patients with implanted pacemaker, defibrillator, nerve stimulator or other active
             electronic medical devices; sensitive to conductive hydrogels used on
             electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS)
             electrodes typically used for TTFields studies.